Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Sales (2019 - 2025)

Historic Return on Sales for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to 0.51%.

  • Keros Therapeutics' Return on Sales rose 1359700.0% to 0.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year increase of 2887100.0%. This contributed to the annual value of 52.78% for FY2024, which is 9604200.0% up from last year.
  • Latest data reveals that Keros Therapeutics reported Return on Sales of 0.51% as of Q3 2025, which was up 1359700.0% from 1.69% recorded in Q2 2025.
  • Keros Therapeutics' 5-year Return on Sales high stood at 15885.0% for Q1 2021, and its period low was 5410.0% during Q3 2023.
  • Its 5-year average for Return on Sales is 438.53%, with a median of 5.82% in 2022.
  • Per our database at Business Quant, Keros Therapeutics' Return on Sales surged by 158878100bps in 2021 and then plummeted by -158863400bps in 2022.
  • Quarter analysis of 5 years shows Keros Therapeutics' Return on Sales stood at 0.39% in 2021, then crashed by -1400bps to 5.82% in 2022, then crashed by -5486bps to 324.86% in 2023, then soared by 95bps to 15.13% in 2024, then surged by 97bps to 0.51% in 2025.
  • Its Return on Sales stands at 0.51% for Q3 2025, versus 1.69% for Q2 2025 and 0.7% for Q1 2025.